Jupiter, Florida February 12, 2013. CHS Pharma Inc. an emerging pharmaceutical company has acquired the Intellectual Property Portfolio for the Treatment and Prevention of Cancer and Prevention of Age Related Diseases from Florida Atlantic University Research Corporation located in Boca Raton, Florida and the Hospital for Special Surgery affiliated with the Weill Cornell Medical College located in New York City, New York. The acquired Intellectual Property is based on the research by Distinguished Research Professor Dr. Herbert Weissbach, former Roche Executive, member of the National Academy of Sciences, and the Director of the Center for Molecular Biology and Biotechnology at FAU’s Jupiter campus. According to the studies conducted by Dr. Weissbach and his research team, cancer cells are selectively targeted and killed while normal healthy cells are protected. The age related studies have shown that by preconditioning cells, heart attack, stroke, and diseases such as Dry Macular Degeneration, a retina disease leading to blindness, can be mitigated.
CHS Pharma co-Founder and Chief Executive Officer, Stephen Chakoff stated that this milestone will significantly increase the value of our company and position us to enter into strategic partnerships leading to New Drug Approvals. CHS Pharma’s first focus is a topical gel treatment for a precancerous skin condition known as Actinic Keratosis (AK). Actinic Keratosis is a major healthcare problem affecting the growing “baby boomer” population. If left untreated 65% of AK results in Squamous Cell Carcinomas, and 36% will result in Basal Cell Carcinomas.
For further information contact.
Saeid Rezvankhah, Chief Operating Officer
sr@chspharma.com
561 748 9393 telephone
www.chspharma.com
